Skip to main navigation Skip to search Skip to main content

Lisdexamfetamine dimesylate

  • Josephine Elia
  • , Chris Easley
  • , Peter Kirkpatrick
  • Children's Hospital of Philadelphia
  • IQVIA Inc.
  • Nature Reviews Drug Discovery

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Lisdexamfetamine dimesylate (Vyvanse; New River Pharmaceuticals/Shire), a prodrug of D-amphetamine, was approved by the US FDA in February 2007 for the treatment of attention-deficit/hyperactivity disorder.

Original languageEnglish
Pages (from-to)343-344
Number of pages2
JournalNature Reviews Drug Discovery
Volume6
Issue number5
DOIs
StatePublished - May 2007
Externally publishedYes

Fingerprint

Dive into the research topics of 'Lisdexamfetamine dimesylate'. Together they form a unique fingerprint.

Cite this